XML 51 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6
Financial Instruments
12 Months Ended
Dec. 31, 2012
Financial Instruments [Abstract]  
Financial Instruments

2.  Financial Instruments

 

A summary of financial instruments measured at fair value as of December 31, 2012 and 2011 is as follows (in thousands):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2012

Level 1

 

Level 2

 

Level 3

 

Total

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

Money market funds

$

--

 

$

1,319 

 

$

--

 

$

1,319 

Restricted securities:

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

--

 

 

323 

 

 

--

 

 

323 

Total assets

 

--

 

 

1,642 

 

 

--

 

 

1,642 

Long-term liabilities:

 

 

 

 

 

 

 

 

 

 

 

Contingent consideration

 

--

 

 

--

 

 

(1,912)

 

 

(1,912)

Total liabilities

 

--

 

 

--

 

 

(1,912)

 

 

(1,912)

 

 

 

 

 

 

 

 

 

 

 

 

Net assets (liabilities)

$

--

 

$

1,642 

 

$

(1,912)

 

$

(270)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2011

Level 1

 

Level 2

 

Level 3

 

Total

Cash equivalents:

 

 

 

 

 

 

 

 

 

 

 

Money market funds

$

--

 

$

7,334 

 

$

--

 

$

7,334 

Restricted securities:

 

 

 

 

 

 

 

 

 

 

 

Money market funds

 

--

 

 

5,312 

 

 

--

 

 

5,312 

Total assets

$

--

 

$

12,646 

 

$

--

 

$

12,646 

 

The Company used prices quoted from its investment management companies to determine the Level 2 valuation of its investments in money market funds and securities.  The Company recorded contingent consideration liability, classified as Level 3, as a result of its acquisition of Hemosphere in May 2012.  Refer to Note 4 for further discussion of the Level 3 contingent consideration liability.  Changes in fair value of Level 3 liabilities are listed below (in thousands): 

 

 

 

 

 

 

 

Contingent Consideration

Balance as of December 31, 2011

$

--

Discounted value of contingent consideration at acquisition

 

1,840 

Loss on remeasurement of contingent consideration

 

72 

Balance as of December 31, 2012

$

1,912